Germany approves first human trials for coronavirus vaccine

This will see 200 healthy people between the age of 18 and 55 receive several variants of the vaccine, developed by German biotech company BioNTech, as scientists examine its efficacy in providing immunity against the virus. Related: Coronavirus crisis around the world (Photos) Germany follows the UK in approving a human trial after health secretary Matt Hancock announced scientists at Oxford University will begin testing a vaccine on people this Thursday. In March, authorities gave the green light for another clinical trial for a vaccine candidate developed by the country’s Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio.